World Health Organization Sounds Concern Over Acute Scarcity of Weight-Loss Injections
Under 10% of patients eligible to benefit from obesity jabs like Wegovy are able to get them, warns the WHO as it releases its initial advice on the medications.
With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is advocating for increased and just access to GLP-1 medication.
Based on estimates, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"Our latest guidance recognises that obesity is a lifelong illness that can be treated with thorough and continuous support," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are key obstacles to widespread availability to the injections that can assist patients in reducing considerable weight, says the body.
Weight-Loss Drug Shortage
Despite the present most optimistic scenario, the manufacturing of GLP-1 therapies could only cover around 100 million people – fewer than 10% of the global need, per the health organization.
The recommendation calls on nations and manufacturers to expand availability, via measures such as patent sharing.
Exclusive production rights on semaglutide – the main component of a leading brand – is scheduled to end in several countries in 2026.
How Weight-Loss Jabs Work
These medications mimick a biological compound to reduce digestion speed, reduce hunger and increase the sense of being full so users consume fewer calories.
Individuals usually start to lose weight within a few weeks of beginning the regular doses.
Research indicates people may put most of the weight back on within a year of discontinuing the medication, when their normal food cravings return.
To be carrying excess weight raises your likelihood for developing medical conditions, like diabetes, cardiovascular issues, brain attack, and some cancers.
Excess weight concerns people in every country and was responsible for 3.7 million deaths worldwide in 2024, as per the health agency.
